Cypherpunk Technologies (CYPH) Stock Price, News & Analysis

Company Overview

Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc., is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Cypherpunk is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development.

Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and now trades on the NASDAQ under the ticker CYPH. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.

Key Stats

• Today's Range: $1.71 to $2.30
• 50-Day Range: $0.59 to $2.27
• 52-Week Range: $0.27 to $3.70
• Volume: 18.20 million shs
• Average Volume: 7.64 million shs
• Market Capitalization: $244.62 million
• P/E Ratio: 4.05
• Dividend Yield: N/A
• Price Target: $1.60
• Consensus Rating: Hold

Cypherpunk Technologies Stock Analysis - MarketRank™

Cypherpunk Technologies scored higher than 29% of companies evaluated by MarketBeat, and ranked 761st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Cypherpunk Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Downside Risk

Cypherpunk Technologies has a consensus price target of $1.60, representing about 29.5% downside from its current price of $2.27.

Amount of Analyst Coverage

Cypherpunk Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cypherpunk Technologies is 4.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cypherpunk Technologies is 4.05, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.

Price to Book Value per Share Ratio

Cypherpunk Technologies has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.47% of the float of Cypherpunk Technologies has been sold short.

Short Interest Ratio / Days to Cover

Cypherpunk Technologies has a short interest ratio ("days to cover") of 5.22.

Change versus previous month

Short interest in Cypherpunk Technologies has recently decreased by 7.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cypherpunk Technologies does not currently pay a dividend.

Dividend Growth

Cypherpunk Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Cypherpunk Technologies has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cypherpunk Technologies this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for CYPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cypherpunk Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cypherpunk Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,400.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Cypherpunk Technologies is held by insiders.

Percentage Held by Institutions

30.46% of the stock of Cypherpunk Technologies is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CYPH
• Previous Symbol: NASDAQ:LPTX
• CIK: 1509745
• Web: www.leaptx.com
• Phone: (617) 714-0360
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Cypherpunk Technologies: $1.60
• High Price Target: $1.60
• Low Price Target: $1.60
• Potential Upside/Downside: -29.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.56
• Trailing P/E Ratio: 4.05
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.76%
• Return on Assets: -19.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 79.19
• Quick Ratio: 79.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 107,760,000
• Free Float: 103,992,000
• Market Cap: $244.62 million
• Optionable: Optionable
• Beta: 0.33